DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 2386--------------------------------------------------
       (Abst.) Inebilizumab (MEDI-551)--results from phase 1 study
       By: agate Date: February 2, 2019, 1:40 am
       ---------------------------------------------------------
       Abstract, "Safety and tolerability of inebilizumab (MEDI-551),
       an anti-CD19 monoclonal antibody, in patients with relapsing
       forms of MS:  Results from a phase 1, randomised,
       placebo-controlled, escalating  intravenous and subcutaneous
       dose study" in Multiple Sclerosis Journal (February 1, 2019;
       first published November 2017):
  HTML https://journals.sagepub.com/doi/abs/10.1177/1352458517740641
       *****************************************************